Cue Biopharma CUE Insider Ownership

Updated Oct 16, 2026

Over the past year, CUE insiders bought $99,747 of stock and sold $2.43 million on the open market.

• Cue Biopharma's open-market purchases in the past 12 months came from one insider, and its sales from 3 insiders.
• Among CUE insiders, Pasha Sarraf (Director) bought the most stock on the open market in the past 12 months: $99,747, most recently on December 30, 2025.
• On the sell side, Shao-Lee Lin (Chief Executive Officer) led open-market sales of Cue Biopharma stock over the past 12 months with $1.91 million, most recently on October 12, 2026.
• Business Quant data shows Cue Biopharma insiders holding 1.02Mn shares in total in their latest Form 4 filings, up 194.01% from 345.24K shares at the end of Q2 2026.
• Cue Biopharma insiders report no indirect holdings: all 1.02Mn shares are held directly.
• Per Business Quant, 13 insiders of CUE hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Cue Biopharma's top three insider holders by shares held are Shao-Lee Lin (Chief Executive Officer, 694.91K shares), Sumita Ray (Chief Legal Compliance Officer, 116.7K shares) and Michael Vincent Meluzio (VP, Principal Accounting Officer, 47.82K shares).
• Shao-Lee Lin alone accounts for 68.46% of the shares held by Cue Biopharma insiders.
• Institutions accounted for 25.88% of CUE's outstanding shares in Q2 2026, insiders about 16.01% per their latest Form 4 filings, and other investors, including the public, about 58.11%.
• In the past year, 16 insiders of Cue Biopharma submitted 35 Form 4 filings reporting trades, awards or other transactions.
• Insider figures for CUE include Form 4 filings through October 14, 2026.